- Algernon Pharmaceuticals (AGN) has announced plans for a 180-patient, 90-day Phase 2b clinical study of NP-120 for chronic cough in Q3 of 2023
- Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert to discuss the upcoming study
- Following discussions with the U.S. FDA, the company plans to file an investigational new drug (IND) application shortly
- Algernon Pharmaceuticals is a Canadian clinical-stage drug development and repurposing company
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$2.25
Algernon Pharmaceuticals (AGN) has announced plans for a 180-patient, 90-day Phase 2b clinical study of NP-120 for chronic cough in Q3 of 2023.
Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough.
The decision to advance the study is based on positive data previously reported on July 28, 2022, from the company’s Phase 2a study of Idiopathic Pulmonary Fibrosis (IPF) and chronic cough, where Ifenprodil showed a significant improvement in mean objective 24-hour and waking cough counts in patients after 4 and 12 weeks.
Algernon previously announced on January 14, 2022, that it had received positive feedback from the U.S. Food and Drug Administration (U.S. FDA) at its pre-Investigational New Drug (pre-IND) meeting for its investigation of Ifenprodil solely for the treatment of chronic cough. The company has since engaged in further discussions with the U.S. FDA and plans to file an investigational new drug (IND) application shortly.
While the company originally planned to focus on IPF in a Phase 2b study, Algernon has now decided to pursue a chronic cough study first and delay planning its IPF Phase 2b study for Ifenprodil until a later date.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert to discuss the upcoming study.
“The design of Phase 2 studies in chronic cough have been validated in trials conducted by Merck & Co and Bellus Health. By mirroring the design of those studies, Algernon will have a direct benchmark for comparison and, if successful, a clear regulatory path for Ifenprodil for the treatment of chronic cough.”
Algernon Pharmaceuticals is a Canadian clinical-stage drug development and repurposing company addressing global unmet medical needs, including stroke, chronic kidney disease and IPF with chronic cough.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$2.25.
